CA3250301A1 - COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULES - Google Patents
COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULESInfo
- Publication number
- CA3250301A1 CA3250301A1 CA3250301A CA3250301A CA3250301A1 CA 3250301 A1 CA3250301 A1 CA 3250301A1 CA 3250301 A CA3250301 A CA 3250301A CA 3250301 A CA3250301 A CA 3250301A CA 3250301 A1 CA3250301 A1 CA 3250301A1
- Authority
- CA
- Canada
- Prior art keywords
- combination
- antigen binding
- fusion proteins
- binding molecules
- cytokine fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335697P | 2022-04-27 | 2022-04-27 | |
| US63/335,697 | 2022-04-27 | ||
| PCT/US2023/019989 WO2023212056A2 (en) | 2022-04-27 | 2023-04-26 | Combination of cytokine fusion proteins with cd8 antigen binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3250301A1 true CA3250301A1 (en) | 2023-11-02 |
Family
ID=88519563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3250301A Pending CA3250301A1 (en) | 2022-04-27 | 2023-04-26 | COMBINATION OF CYTOKINE FUSION PROTEINS WITH CD8 ANTIGEN-BINDING MOLECULES |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250339519A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4514397A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515470A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250027597A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119546343A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023259161A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250301A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400664A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023212056A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2026162740A1 (en) * | 2025-01-31 | 2026-08-06 | Astrazeneca Ab | Cd8-binding cytokine engager combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| JP2020533971A (ja) * | 2017-08-28 | 2020-11-26 | アルター・バイオサイエンス・コーポレーション | Il−15をベースとするil−7及びil−21への融合物 |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230086765A (ko) * | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| KR20230112632A (ko) * | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022245500A1 (en) * | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
-
2023
- 2023-04-26 CN CN202380050634.5A patent/CN119546343A/zh active Pending
- 2023-04-26 JP JP2024563188A patent/JP2025515470A/ja active Pending
- 2023-04-26 WO PCT/US2023/019989 patent/WO2023212056A2/en not_active Ceased
- 2023-04-26 KR KR1020247039383A patent/KR20250027597A/ko active Pending
- 2023-04-26 AU AU2023259161A patent/AU2023259161A1/en active Pending
- 2023-04-26 CA CA3250301A patent/CA3250301A1/en active Pending
- 2023-04-26 US US18/859,452 patent/US20250339519A1/en active Pending
- 2023-04-26 EP EP23797206.2A patent/EP4514397A4/en active Pending
- 2023-04-27 TW TW112115849A patent/TW202400664A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025515470A (ja) | 2025-05-15 |
| KR20250027597A (ko) | 2025-02-26 |
| EP4514397A2 (en) | 2025-03-05 |
| AU2023259161A1 (en) | 2024-11-28 |
| TW202400664A (zh) | 2024-01-01 |
| WO2023212056A2 (en) | 2023-11-02 |
| US20250339519A1 (en) | 2025-11-06 |
| WO2023212056A3 (en) | 2023-12-07 |
| EP4514397A4 (en) | 2026-05-20 |
| CN119546343A (zh) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3972987T5 (da) | Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf | |
| EP4232071A4 (en) | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION | |
| AU2022242125A1 (en) | Proteins comprising cd3 antigen binding domains and uses thereof | |
| AU2021403658A9 (en) | Recombinant cd3 binding proteins and their use | |
| EP4126965A4 (en) | ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS | |
| EP4168124A4 (en) | ANTI-PD-1 ANTIBODIES AND FUSION PROTEINS | |
| EP4274614A4 (en) | ANTI-PD-L1 ANTIBODIES AND CORRESPONDING FUSION PROTEINS | |
| AU2024265777A1 (en) | Methods of using il-18 fusion proteins | |
| HK40123367A (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| EP3983450A4 (en) | ANTI-PD-L1/ANTI-LAG-3 PROTEINS WITH MULTIPLE ANTIGEN BINDING AND METHODS FOR THEIR USE | |
| WO2023212056A3 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules | |
| AU2024334289A1 (en) | Anti-il-13 multispecific antibody constructs and uses thereof | |
| EP4286520A4 (en) | Antigen-binding protein and use thereof | |
| EP4330277A4 (en) | Multimerization of binding molecules with a variant of the constant region of an antibody | |
| CA3301507A1 (en) | Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof | |
| CA3265178A1 (en) | Antigen-binding proteins and their uses | |
| CA3283890A1 (en) | Multispecific antigen binding proteins and uses thereof | |
| HK40103094A (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| CA3284529A1 (en) | Antigen binding molecules and methods of use | |
| HK40113395A (en) | Antigen binding proteins and uses thereof | |
| HK40093081A (en) | Recombinant cd3 binding proteins and their use | |
| HK40103847A (en) | Anti-ctla-4 binding proteins and methods of use thereof | |
| CA3292582A1 (en) | Antibodies targeting xcl1 and methods of using the same | |
| HK40084390A (en) | Anti-ctla-4 binding proteins and methods of use thereof | |
| AU2023903973A0 (en) | Binding proteins and methods and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241022 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241204 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20241204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250106 |